Q. “The shift from AI-enabled Genome analysis to AI-assisted Genome design marks a new frontier in biotechnology.” Discuss its ethical and...
Question
Q. “The shift from AI-enabled Genome analysis to AI-assisted Genome design marks a new frontier in biotechnology.” Discuss its ethical and biosecurity implications.
(10 marks 150 Words)
Model Answer
Q. “The shift from AI-enabled Genome analysis to AI-assisted Genome design marks a new frontier in biotechnology.” Discuss its ethical and biosecurity implications.
(10 marks 150 Words)
Paper
GS III
Subject
Science & Technology
Syllabus as Per Notification
Awareness in the fields of IT, Space, Computers, Robotics, Nano-technology, Bio-technology and issues relating to Intellectual Property Rights.
Topic
AI in Genome Design
Approach:
Introduction
Introduce by mentioning Artificial Intelligence (AI) is shifting biology from “reading” genomes to “writing” biological designs.
Body
Briefly explain AI-enabled Genome analysis and AI-assisted Genome design for the context.
Ethical and Biosecurity Implications of AI-assisted Genome Design
From “reading” to “writing” Genomes, Demonstrated Biological Functionality and Dual-Use Risks, lowering barriers to biological Misuse, Unpredictability of novel biological designs, Difficulty in detecting novel biological threats, Accountability for AI-designed biology.
Way Forward
Adopting risk-tiered governance, strengthening digital biosecurity, ensuring responsible access and human oversight, Enabling responsible innovation.
Conclusion
Conclude by emphasising AI-enabled biological innovation remains safe, trustworthy and socially beneficial, while preserving scientific openness and preventing misuse.
Context
Researchers at Stanford University and the Arc Institute used artificial intelligence (AI) to design complete genomes of bacteriophages - viruses that infect bacteria.
Introduction
Artificial Intelligence is transforming genomics from understanding existing genetic information to helping create new genetic sequences. This shift from “reading” genomes to “writing” biological designs enables scientists to move beyond studying how biological systems work towards designing them for specific purposes. While this can accelerate medical and biotechnology innovations, it also creates new ethical and biosecurity concerns requiring responsible governance.
Body
AI-enabled Genome analysis and AI-assisted Genome design
Dimension
AI-enabled Genome Analysis
AI-assisted Genome Design
Core function
Interprets existing genomic sequences and biological relationships
Generates novel genomic sequences with desired properties
Primary question
“What does this sequence do?”
“What sequence could achieve this function?”
Nature of capability
Focuses on prediction and understanding of genes, variants and biological functions
Moves towards creation and intervention by proposing new biological designs
Human–AI role
AI primarily acts as an analytical tool supporting human researchers
AI acts as a co-designer in the biological design–build–test cycle.
Risk profile
Mainly involves privacy, genomic-data governance, bias and prediction errors
Involves dual-use risks, unintended biological effects, biosecurity threats and accountability
Ethical and Biosecurity Implications of AI-assisted Genome Design
From “reading” to “writing” Genomes
Evo 1 and Evo 2 are AI genome models that analyse DNA patterns and generate novel genomic sequences, marking the shift towards AI-assisted biological design.
BioE3 Policy of DBT is supporting Bio-AI Hubs for data-driven biological research, including biomolecular design, genome diagnostics and synthetic biology, alongside Biofoundries for translating biological discoveries into applications.
Demonstrated Biological Functionality and Dual-Use Risks
Stanford–Arc Institute study used ΦX174 as a design template. Of 285 AI-generated genomes experimentally tested, 16 produced functional phages.
AI-designed phage cocktails overcame resistance in three ΦX174-resistant E. coli strains, showing both therapeutic potential against Anti-Microbial Resistance and dual-use concerns.
Lowering barriers to biological misuse
AI-assisted genome design can reduce the time, expertise and computational effort required to explore biological designs, potentially widening access to capabilities with dual-use potential.
The large-scale generation and experimental testing of AI-designed bacteriophage genomes demonstrates how AI can accelerate the biological design–build–test cycle.
Unpredictability of novel biological designs
De novo AI-generated sequences (newly designed sequences without direct natural counterpart), may contain biological combinations whose properties are difficult to predict.
Evo-Φ36, an AI-designed bacteriophage (virus that infects bacteria), incorporated DNA-packaging protein from distantly related phage, showing AI ability to generate novel and functional biological combinations.
Difficulty in detecting novel biological threats
AI-generated biological sequences may differ from known natural sequences, making it harder to identify potentially risky designs through conventional similarity-based screening.
De novo genome design expands biological sequence space, requiring assessment of function and risk beyond genetic similarity.
Accountability for AI-designed biology
As AI moves from analysing genomes to generating biological designs, responsibility becomes distributed among AI developers, researchers, laboratories and synthesis providers, creating an accountability challenge for unintended outcomes.
Way Forward
Adopting risk-tiered governance: Applying precautionary approach of the Cartagena Protocol and extending India’s DBT–IBSC biosafety framework to AI-generated biological designs.
Strengthening digital biosecurity: Complementing International Gene Synthesis Consortium (IGSC) type sequence screening with functional and risk-based assessment to identify novel AI-generated sequences.
Ensuring responsible access and human oversight: Implementing graduated access, traceability, auditing and human-in-the-loop review for high-risk AI models and designs before laboratory realisation.
Enabling responsible innovation: Strengthening BioE3 Policy, Bio-AI Hubs and Biofoundries with biosafety-by-design, ethical safeguards and international cooperation.
Conclusion
AI-biotechnology convergence can promote Anti-Microbial Resistance (AMR) solutions, therapeutics and biological innovation, but expanding design capabilities also create novel, difficult-to-predict risks. The objective should be “innovation with responsibility”, combining risk-tiered governance, functional biosecurity screening, human oversight and responsible access. Aligning genome-design governance with OECD AI Principles can ensure that biological innovation remains safe, trustworthy and socially beneficial.